Jason Harris

August 03, 2022

A joint statement from the American Society of Clinical Oncology and the Association of Community Cancer Centers outlines steps to reduce gaps in care for underserved communities.

July 04, 2022

The NCCN guidelines have been amended to include trastuzumab deruxtecan for use in patients with HER2-low metastatic breast cancer and sacituzumab govitecan for use in patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

April 16, 2022

Preliminary findings from the phase 1/2a TEM-GBM study highlight the potential utility of temferon, genetically modified Tie2-expressing monocytes targeting interferon a2 in treating patients with glioblastoma.

April 11, 2022

Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.

March 18, 2022

Radiotherapy treatment has continued to evolve to become both shorter and faster in potentially curing prostate cancer.

February 20, 2022

A post-hoc analysis of 2 studies revealed that patients with advanced prostate cancer receiving apalutamide reported positive wellbeing scores during treatment.

January 29, 2022

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

November 20, 2021

The majority of patients who received telotristat ethyl to treat their carcinoid syndrome reported stable or increased weight at a 6-month follow-up.

November 19, 2021

Patients receiving immune checkpoint inhibitors for renal cell carcinoma or melanoma responded well to the COVID-19 vaccine.

September 24, 2021

Patients with prostate cancer fared better following treatment with magnetic resonance-guided focused ultrasound focal therapy than with radical prostatectomy or radiation therapy, shows study presented at 2021 AUA Annual Meeting.